Literature DB >> 33782512

A normative chart for cognitive development in a genetically selected population.

Jacob Vorstman1,2,3, Elemi J Breetvelt3, Ania M Fiksinski4,5,6,7, Carrie E Bearden8, Anne S Bassett9,10,1,11, René S Kahn2,12, Janneke R Zinkstok2, Stephen R Hooper13, Wanda Tempelaar14,1, Donna McDonald-McGinn15,16, Ann Swillen17,18, Beverly Emanuel15, Bernice Morrow19, Raquel Gur20, Eva Chow10,1, Marianne van den Bree21, Joris Vermeesch17, Stephen Warren22, Michael Owen21, Therese van Amelsvoort23, Stephan Eliez24, Doron Gothelf25,26, Celso Arango27, Wendy Kates28, Tony Simon29, Kieran Murphy30, Gabriela Repetto31, Damian Heine Suner32, Stefano Vicari33, Joseph Cubells22,34, Marco Armando24, Nicole Philip35,36, Linda Campbell37, Sixto Garcia-Minaur38, Maude Schneider24, Vandana Shashi39.   

Abstract

Certain pathogenic genetic variants impact neurodevelopment and cause deviations from typical cognitive trajectories. Understanding variant-specific cognitive trajectories is clinically important for informed monitoring and identifying patients at risk for comorbid conditions. Here, we demonstrate a variant-specific normative chart for cognitive development for individuals with 22q11.2 deletion syndrome (22q11DS). We used IQ data from 1365 individuals with 22q11DS to construct variant-specific normative charts for cognitive development (Full Scale, Verbal, and Performance IQ). This allowed us to calculate Z-scores for each IQ datapoint. Then, we calculated the change between first and last available IQ assessments (delta Z-IQ-scores) for each individual with longitudinal IQ data (n = 708). We subsequently investigated whether using the variant-specific IQ-Z-scores would decrease required sample size to detect an effect with schizophrenia risk, as compared to standard IQ-scores. The mean Z-IQ-scores for FSIQ, VIQ, and PIQ were close to 0, indicating that participants had IQ-scores as predicted by the normative chart. The mean delta-Z-IQ-scores were equally close to 0, demonstrating a good fit of the normative chart and indicating that, as a group, individuals with 22q11DS show a decline in IQ-scores as they grow into adulthood. Using variant-specific IQ-Z-scores resulted in 30% decrease of required sample size, as compared to the standard IQ-based approach, to detect the association between IQ-decline and schizophrenia (p < 0.01). Our findings suggest that using variant-specific normative IQ data significantly reduces required sample size in a research context, and may facilitate a more clinically informative interpretation of IQ data. This approach allows identification of individuals that deviate from their expected, variant-specific, trajectory. This group may be at increased risk for comorbid conditions, such as schizophrenia in the case of 22q11DS.
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Year:  2021        PMID: 33782512      PMCID: PMC9117666          DOI: 10.1038/s41386-021-00988-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  46 in total

1.  Cognitive development in children with 22q11.2 deletion syndrome.

Authors:  Sasja N Duijff; Petra W J Klaassen; Henriette F N Swanenburg de Veye; Frits A Beemer; Gerben Sinnema; Jacob A S Vorstman
Journal:  Br J Psychiatry       Date:  2012-06       Impact factor: 9.319

Review 2.  Systematic review of cognitive development across childhood in Down syndrome: implications for treatment interventions.

Authors:  T Patterson; C M Rapsey; P Glue
Journal:  J Intellect Disabil Res       Date:  2013-04

Review 3.  Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome.

Authors:  Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman
Journal:  Am J Med Genet A       Date:  2018-09-08       Impact factor: 2.802

Review 4.  Dementia in Down's syndrome.

Authors:  Clive Ballard; William Mobley; John Hardy; Gareth Williams; Anne Corbett
Journal:  Lancet Neurol       Date:  2016-04-11       Impact factor: 44.182

5.  Measuring and Estimating the Effect Sizes of Copy Number Variants on General Intelligence in Community-Based Samples.

Authors:  Guillaume Huguet; Catherine Schramm; Elise Douard; Lai Jiang; Aurélie Labbe; Frédérique Tihy; Géraldine Mathonnet; Sonia Nizard; Emmanuelle Lemyre; Alexandre Mathieu; Jean-Baptiste Poline; Eva Loth; Roberto Toro; Gunter Schumann; Patricia Conrod; Zdenka Pausova; Celia Greenwood; Tomas Paus; Thomas Bourgeron; Sébastien Jacquemont
Journal:  JAMA Psychiatry       Date:  2018-05-01       Impact factor: 21.596

6.  Longitudinal changes in intellectual development in children with Fragile X syndrome.

Authors:  Scott S Hall; David D Burns; Amy A Lightbody; Allan L Reiss
Journal:  J Abnorm Child Psychol       Date:  2008-03-18

7.  Course of Cognitive Development From Infancy to Early Adulthood in the Psychosis Spectrum.

Authors:  Josephine Mollon; Anthony S David; Stanley Zammit; Glyn Lewis; Abraham Reichenberg
Journal:  JAMA Psychiatry       Date:  2018-03-01       Impact factor: 21.596

8.  Growth Charts for Children With Down Syndrome in the United States.

Authors:  Babette S Zemel; Mary Pipan; Virginia A Stallings; Waynitra Hall; Kim Schadt; David S Freedman; Phoebe Thorpe
Journal:  Pediatrics       Date:  2015-11       Impact factor: 7.124

9.  Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia.

Authors:  Richard S E Keefe; René S Kahn
Journal:  JAMA Psychiatry       Date:  2017-05-01       Impact factor: 21.596

Review 10.  Premorbid (early life) IQ and later mortality risk: systematic review.

Authors:  G David Batty; Ian J Deary; Linda S Gottfredson
Journal:  Ann Epidemiol       Date:  2006-12-15       Impact factor: 3.797

View more
  1 in total

1.  Untargeted metabolic analysis in dried blood spots reveals metabolic signature in 22q11.2 deletion syndrome.

Authors:  Dorinde Korteling; Marco P Boks; Ania M Fiksinski; Ilja N van Hoek; Jacob A S Vorstman; Nanda M Verhoeven-Duif; Judith J M Jans; Janneke R Zinkstok
Journal:  Transl Psychiatry       Date:  2022-03-09       Impact factor: 6.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.